Workboat Indexes

Markets:

Overview

News

Currencies

International

Treasuries

Cingulate Inc. - Common Stock (NQ:CING)

5.380 +0.030 (+0.56%)

Streaming Delayed Price Updated: 9:30 AM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cingulate Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

April 04, 2023

From Cingulate Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket ↗

March 14, 2023

Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.

Via Benzinga

Why Cingulate Shares Are Trading Higher Today ↗

February 24, 2023

Via Benzinga

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 13, 2023

Via Benzinga

5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions ↗

March 13, 2023

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits...

Via Benzinga

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 13, 2023

Via Benzinga

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...

Via Benzinga

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

March 13, 2023

From Indegene Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 10, 2023

Via Benzinga

Cingulate Inc. (NASDAQ: CING) Featured in Coverage of the 35th Annual Roth Conference

February 28, 2023

Via Investor Brand Network

Tesla, Amazon, Union Pacific, Woodside Energy, Cingulate: Why These 5 Stocks Drawing Investors' Attention Today ↗

February 26, 2023

Via Benzinga

Dow Dips 350 Points; S&P 500 Down Over 1% ↗

February 24, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500...

Via Benzinga

Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 24, 2023

Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 24, 2023

Via Benzinga

Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher ↗

February 24, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...

Via Benzinga

Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today? ↗

February 24, 2023

Nektar Therapeutics (NKTR) stock is taking a beating on Friday following the release of poor Phase 2 clinical trial data.

Via InvestorPlace

Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today? ↗

February 24, 2023

SELLAS Life Sciences (SLS) stock is falling on Friday after the biopharmaceutical company announced a proposed public offering.

Via InvestorPlace

Why Is Bridger Aerospace (BAER) Stock Up 84% Today? ↗

February 24, 2023

Bridger Aerospace (BAER) stock is taking off on Friday after a filing revealed an over 22% stake in the company from a group of investors.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 24, 2023

Via Benzinga

Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

February 24, 2023

Gainers Cingulate Inc (NASDAQ: CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD.

Via Benzinga

Why Is Cingulate (CING) Stock Up 72% Today? ↗

February 24, 2023

Cingulate (CING) stock is on the rise Friday after releasing positive data concerning its ADHD treatment, which is in a Phase 3 trial.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

February 24, 2023

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023 ↗

January 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 04, 2023

Via Benzinga

Cingulate Kickstarts Pivotal Trial For ADHD Candidate, Data Expected In First Half 2023 ↗

January 04, 2023

Cingulate Inc (NASDAQ: CING) has initiated the first Phase 3 clinical trial of its lead candidate CTx-1301, an extended-release tablet formulation of dexmethylphenidate, a compound approved by the FDA...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

Cingulate Inc. - Common Stock (NQ:CING)

All News about Cingulate Inc. - Common Stock

Cooper Tacia acquires Atlantis Marine Contractors, establishes new Civil and Marine Division

Kymeta Wins ONR contract for Ku/Ka multi-band SATCOM

FMD's Vestdavit introduces autonomous recovery system for unmanned vessels

Staying in Touch: Workboat comms evolve to 21st century levels